Cargando…
The Toll-Like Receptor 4 Antagonist Eritoran Protects Mice from Lethal Filovirus Challenge
The 2013-2016 outbreak of Ebola virus (EBOV) in West Africa, which has seen intermittent reemergence since it was officially declared over in February of 2016, has demonstrated the need for the rapid development of therapeutic intervention strategies. Indirect evidence has suggested that the EBOV in...
Autores principales: | Younan, Patrick, Ramanathan, Palaniappan, Graber, Jessica, Gusovsky, Fabian, Bukreyev, Alexander |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Microbiology
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5405229/ https://www.ncbi.nlm.nih.gov/pubmed/28442605 http://dx.doi.org/10.1128/mBio.00226-17 |
Ejemplares similares
-
Effect of the Toll-Like Receptor 4 Antagonist Eritoran on Retinochoroidal Inflammatory Damage in a Rat Model of Endotoxin-Induced Inflammation
por: Ekici, Feyzahan, et al.
Publicado: (2014) -
Effects of Overexpression of the Egyptian Fruit Bat Innate Immune Genes on Filovirus Infections in the Host Cells
por: Kuzmin, Ivan V., et al.
Publicado: (2021) -
Eritoran insight for influenza treatment
por: Baas, Tracey
Publicado: (2013) -
Eritoran: the evidence of its therapeutic potential in sepsis
por: Raja, Shahzad G., et al.
Publicado: (2007) -
Evaluation of eritoran tetrasodium (E5564), a TLR4 antagonist, on the QTc interval in healthy subjects
por: Nagy, CF, et al.
Publicado: (2011)